2010
DOI: 10.1111/j.1423-0410.2010.01360.x
|View full text |Cite
|
Sign up to set email alerts
|

Payment, compensation and replacement - the ethics and motivation of blood and plasma donation

Abstract: The supply of blood and plasma to produce haemotherapies varies around the world, but all environments need donors to furnish the raw material. Many countries still lack adequate supply, and the question of what amounts of blood and plasma are required for optimal treatment is still unresolved. The issue of compensating donors has been a controversial and emotive one in blood transfusion for many decades. Donors are conventionally classified as paid, voluntary or replacement, and a level of stigma, based on sa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
92
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
3
3

Relationship

0
6

Authors

Journals

citations
Cited by 90 publications
(100 citation statements)
references
References 56 publications
1
92
0
Order By: Relevance
“…For instance, in 2006 the US health care system used usage rates for plasma products. For instance, in 2006 the US health care system used 105 grams per/1,000 people of the dominant plasma product (immunoglobulin) 105 grams per/1,000 people of the dominant plasma product (immunoglobulin) which was more than 250 percent of the rate in Italy, the United Kingdom, Germany, which was more than 250 percent of the rate in Italy, the United Kingdom, Germany, the Netherlands, and Japan (Flood et al 2006), suggesting that the noncompensated the Netherlands, and Japan (Flood et al 2006), suggesting that the noncompensated plasma collection system might be limiting potential usage in many countries. plasma collection system might be limiting potential usage in many countries.…”
Section: S-present: Demand Growth Safety Volunteerismmentioning
confidence: 99%
See 4 more Smart Citations
“…For instance, in 2006 the US health care system used usage rates for plasma products. For instance, in 2006 the US health care system used 105 grams per/1,000 people of the dominant plasma product (immunoglobulin) 105 grams per/1,000 people of the dominant plasma product (immunoglobulin) which was more than 250 percent of the rate in Italy, the United Kingdom, Germany, which was more than 250 percent of the rate in Italy, the United Kingdom, Germany, the Netherlands, and Japan (Flood et al 2006), suggesting that the noncompensated the Netherlands, and Japan (Flood et al 2006), suggesting that the noncompensated plasma collection system might be limiting potential usage in many countries. plasma collection system might be limiting potential usage in many countries.…”
Section: S-present: Demand Growth Safety Volunteerismmentioning
confidence: 99%
“…Demand for plasma products has also increased rapidly. For instance, the annual supply of albumin-often used in the treatment of shock and severe burnsannual supply of albumin-often used in the treatment of shock and severe burnsincreased 20-fold from 30,000 pints at the end of the war to over 600,000 pints by increased 20-fold from 30,000 pints at the end of the war to over 600,000 pints by 1990 (Peters 1996) and intravenous immunoglobulin-often used to fi ght infec-1990infec- (Peters 1996 and intravenous immunoglobulin-often used to fi ght infections-has increased more than fi ve-fold from 15 to 80 tons from 1990 to 2006 tions-has increased more than fi ve-fold from 15 to 80 tons from 1990 to 2006(Flood et al 2006. (Flood et al 2006).…”
Section: S-present: Demand Growth Safety Volunteerismmentioning
confidence: 99%
See 3 more Smart Citations